A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

(1) Icahn School of Medicine at Mount Sinai,New York,United States of America

(2) University of Calgary,Calgary,Canada

(3) Imelda General Hospital,Bonheiden,Belgium

(4) AZ Delta,Roeselare,Belgium

(5) Hepato-Gastroenterologie HK, s.r.o.,Hradec Králové,Czech Republic

(6) Bezmialem Vakif University School Of Medicine,Gastroenterology,İstanbul,Turkey

(7) Medical University of Vienna,Vienna,Austria

(8) Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica,Rome,Italy

(9) Service de Gastroentérologie et Nutrition Clinique,Nice,France

(10) Oxford University Hospitals,Oxford,United Kingdom

(11) Istituto Clinico Humanitas,Millan,Italy

(12) 12University of California San Diego,La Jolla,United States of America

(13) University of Leuven,Leuven,Belgium

(14) University of California,Los Angeles,United States of America

(15) 15University Hospital Schleswig-Holstein,Kiel,Germany

(16) AbbVie Inc.,North Chicago,United States of America

(17) Academic Medical Center,Amsterdam,Netherlands



This item was part of UEG Week 2017

This item can be cited as: United European Gastroenterology Journal 2017; 5 (Supplement 1)

You may be interested in:

Mucosal Healing in Crohn´s Disease and Ulcerative Colitis How should it be assessed and how important is it
English, Presentation, Clinical aspects, Medical management, Colon, Capsule technologies, Capsule Endoscopy, Investigation and Diagnosis, Inflammatory bowel disease, Colonoscopy and sigmoidoscopy, Small intestine, Endoscopic scoring systems, 2010

Categorisation:

  • Format
    • Abstract
  • Year
    • 2017